Limits...
Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells.

Lamers D, Schlich R, Greulich S, Sasson S, Sell H, Eckel J - J. Cell. Mol. Med. (2010)

Bottom Line: CM itself does not contain fatty acids, but CM in combination with OA markedly enhances proliferation of hVSMC in a synergistic way.Both the nuclear factor (NF)-κB and the mammalian target of rapamycin (mTOR) pathway were synergistically activated under these conditions and found to be essential for hVSMC proliferation.Expression of iNOS and production of nitric oxide were only enhanced under these conditions and were paralleled by a marked release of VEGF.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany.

Show MeSH

Related in: MedlinePlus

Effects of OA, CM and the combination of both on iNOS expression, VEGF concentration and nitric oxide production and impact of VEGF and NOS inhibitor L-NAME on proliferation. hVSMC were treated as described in the legend to Figure 3. (A) Total cell lysates were resolved by SDS-PAGE and immunoblotted with a specific iNOS antibody. Data are mean values ± S.E.M. of three independent experiments. All data were normalized to the level of actin expression and are expressed relative to the control. (B) After 24 hrs the supernatant were collected and VEGF concentration was measured by ELISA assay. (C) hVSMC were subsequently analysed for their capacity to produce nitric oxide as described in the ‘Materials’ section. As positive control (PC), cells were treated for 30 min. prior the beginning of the experiment with SNAP. (D) Cells were treated with 125 pg VEGF, OA and the combination of VEGF and OA (VEGFOA) for 18 hrs. Proliferation was measured by the incorporation of BrdU into DNA. (E) Cells were treated with CM, OA and CMOA as described in the legend to Figure 3 with or without 1 mM L-NAME for 24 hrs. Data are means ± S.E.M. *P < 0.05 compared to untreated hVSMC (n = 3); #P < 0.05 compared to L-NAME treated hVSMC (n = 3).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3822630&req=5

fig06: Effects of OA, CM and the combination of both on iNOS expression, VEGF concentration and nitric oxide production and impact of VEGF and NOS inhibitor L-NAME on proliferation. hVSMC were treated as described in the legend to Figure 3. (A) Total cell lysates were resolved by SDS-PAGE and immunoblotted with a specific iNOS antibody. Data are mean values ± S.E.M. of three independent experiments. All data were normalized to the level of actin expression and are expressed relative to the control. (B) After 24 hrs the supernatant were collected and VEGF concentration was measured by ELISA assay. (C) hVSMC were subsequently analysed for their capacity to produce nitric oxide as described in the ‘Materials’ section. As positive control (PC), cells were treated for 30 min. prior the beginning of the experiment with SNAP. (D) Cells were treated with 125 pg VEGF, OA and the combination of VEGF and OA (VEGFOA) for 18 hrs. Proliferation was measured by the incorporation of BrdU into DNA. (E) Cells were treated with CM, OA and CMOA as described in the legend to Figure 3 with or without 1 mM L-NAME for 24 hrs. Data are means ± S.E.M. *P < 0.05 compared to untreated hVSMC (n = 3); #P < 0.05 compared to L-NAME treated hVSMC (n = 3).

Mentions: We determined iNOS expression in hVSMC after incubation with CM, OA and CMOA for 24 hrs (Fig. 6A). CM and OA treatment had no significant effect on iNOS expression. However, the combination of both induced a 2.3-fold increase of iNOS expression in SMC. It is well established that an increased iNOS expression leads to an enhanced VEGF production in different cell types [18–20]. CM alone contains 122 ± 6 pg/ml VEGF (n = 16). Both CM and OA increased VEGF concentration in SMC medium 2.1- and 2.3-fold, respectively, taking into account the endogenous VEGF content of CM (Fig. 6B). In addition, CMOA increased VEGF concentration in a synergistic manner (5.5-fold). Concomitantly, a significant increase in nitric oxide production by 1.5-fold was observed in hVSMC after incubation with the combination CMOA (Fig. 6C). VEGF treatment showed a significant effect (2.5-fold) on proliferation and the combination of VEGF and OA markedly enhanced the proliferation in an additive way (5-fold) (Fig. 6D). Inhibition of NOS by L-nitro-l-arginine methyl ester (NAME) had no effect on the proliferation induced by CM and OA alone, yet it completely abolished the synergistic effect of the two stimuli. Notably, an additive proliferative effect of CM and OA was still observed (Fig. 6E).


Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smooth muscle cells.

Lamers D, Schlich R, Greulich S, Sasson S, Sell H, Eckel J - J. Cell. Mol. Med. (2010)

Effects of OA, CM and the combination of both on iNOS expression, VEGF concentration and nitric oxide production and impact of VEGF and NOS inhibitor L-NAME on proliferation. hVSMC were treated as described in the legend to Figure 3. (A) Total cell lysates were resolved by SDS-PAGE and immunoblotted with a specific iNOS antibody. Data are mean values ± S.E.M. of three independent experiments. All data were normalized to the level of actin expression and are expressed relative to the control. (B) After 24 hrs the supernatant were collected and VEGF concentration was measured by ELISA assay. (C) hVSMC were subsequently analysed for their capacity to produce nitric oxide as described in the ‘Materials’ section. As positive control (PC), cells were treated for 30 min. prior the beginning of the experiment with SNAP. (D) Cells were treated with 125 pg VEGF, OA and the combination of VEGF and OA (VEGFOA) for 18 hrs. Proliferation was measured by the incorporation of BrdU into DNA. (E) Cells were treated with CM, OA and CMOA as described in the legend to Figure 3 with or without 1 mM L-NAME for 24 hrs. Data are means ± S.E.M. *P < 0.05 compared to untreated hVSMC (n = 3); #P < 0.05 compared to L-NAME treated hVSMC (n = 3).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3822630&req=5

fig06: Effects of OA, CM and the combination of both on iNOS expression, VEGF concentration and nitric oxide production and impact of VEGF and NOS inhibitor L-NAME on proliferation. hVSMC were treated as described in the legend to Figure 3. (A) Total cell lysates were resolved by SDS-PAGE and immunoblotted with a specific iNOS antibody. Data are mean values ± S.E.M. of three independent experiments. All data were normalized to the level of actin expression and are expressed relative to the control. (B) After 24 hrs the supernatant were collected and VEGF concentration was measured by ELISA assay. (C) hVSMC were subsequently analysed for their capacity to produce nitric oxide as described in the ‘Materials’ section. As positive control (PC), cells were treated for 30 min. prior the beginning of the experiment with SNAP. (D) Cells were treated with 125 pg VEGF, OA and the combination of VEGF and OA (VEGFOA) for 18 hrs. Proliferation was measured by the incorporation of BrdU into DNA. (E) Cells were treated with CM, OA and CMOA as described in the legend to Figure 3 with or without 1 mM L-NAME for 24 hrs. Data are means ± S.E.M. *P < 0.05 compared to untreated hVSMC (n = 3); #P < 0.05 compared to L-NAME treated hVSMC (n = 3).
Mentions: We determined iNOS expression in hVSMC after incubation with CM, OA and CMOA for 24 hrs (Fig. 6A). CM and OA treatment had no significant effect on iNOS expression. However, the combination of both induced a 2.3-fold increase of iNOS expression in SMC. It is well established that an increased iNOS expression leads to an enhanced VEGF production in different cell types [18–20]. CM alone contains 122 ± 6 pg/ml VEGF (n = 16). Both CM and OA increased VEGF concentration in SMC medium 2.1- and 2.3-fold, respectively, taking into account the endogenous VEGF content of CM (Fig. 6B). In addition, CMOA increased VEGF concentration in a synergistic manner (5.5-fold). Concomitantly, a significant increase in nitric oxide production by 1.5-fold was observed in hVSMC after incubation with the combination CMOA (Fig. 6C). VEGF treatment showed a significant effect (2.5-fold) on proliferation and the combination of VEGF and OA markedly enhanced the proliferation in an additive way (5-fold) (Fig. 6D). Inhibition of NOS by L-nitro-l-arginine methyl ester (NAME) had no effect on the proliferation induced by CM and OA alone, yet it completely abolished the synergistic effect of the two stimuli. Notably, an additive proliferative effect of CM and OA was still observed (Fig. 6E).

Bottom Line: CM itself does not contain fatty acids, but CM in combination with OA markedly enhances proliferation of hVSMC in a synergistic way.Both the nuclear factor (NF)-κB and the mammalian target of rapamycin (mTOR) pathway were synergistically activated under these conditions and found to be essential for hVSMC proliferation.Expression of iNOS and production of nitric oxide were only enhanced under these conditions and were paralleled by a marked release of VEGF.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Düsseldorf, Germany.

Show MeSH
Related in: MedlinePlus